• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Research Briefing on 6-Chloro-2-ethynylimidazo[1,2-a]pyridine (CAS: 1171937-69-1) in Chemical Biology and Pharmaceutical Applications

The compound 6-chloro-2-ethynylimidazo[1,2-a]pyridine (CAS: 1171937-69-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential as a versatile scaffold for drug discovery. This heterocyclic compound, characterized by its imidazopyridine core and ethynyl functional group, has demonstrated promising biological activities, particularly in the modulation of protein-protein interactions and enzyme inhibition. Recent studies have explored its applications in targeting neurodegenerative diseases, oncology, and infectious diseases, making it a compound of high interest for medicinal chemists and pharmacologists.

One of the key areas of research involving 6-chloro-2-ethynylimidazo[1,2-a]pyridine is its role as a kinase inhibitor. Kinases are critical enzymes involved in signal transduction pathways, and their dysregulation is often associated with cancer and other proliferative diseases. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific tyrosine kinases, with IC50 values in the low nanomolar range. The study highlighted the compound's ability to bind to the ATP-binding site of kinases, thereby disrupting their catalytic activity. These findings suggest that 6-chloro-2-ethynylimidazo[1,2-a]pyridine could serve as a lead compound for the development of novel anticancer therapeutics.

In addition to its kinase inhibitory properties, recent research has explored the compound's potential in neurodegenerative disease therapy. A study published in ACS Chemical Neuroscience in early 2024 reported that 6-chloro-2-ethynylimidazo[1,2-a]pyridine derivatives exhibit neuroprotective effects in models of Alzheimer's disease. The compounds were found to reduce amyloid-beta aggregation and mitigate oxidative stress in neuronal cells. These effects were attributed to the compound's ability to modulate the activity of key enzymes involved in amyloidogenesis and redox homeostasis. The study's authors proposed that further optimization of the scaffold could yield clinically viable candidates for neurodegenerative disease treatment.

The synthetic accessibility of 6-chloro-2-ethynylimidazo[1,2-a]pyridine has also been a focus of recent investigations. A 2023 publication in Organic Letters described an efficient, scalable synthesis route for this compound and its derivatives, utilizing palladium-catalyzed cross-coupling reactions. This methodological advancement has facilitated the production of diverse analogs for structure-activity relationship (SAR) studies, enabling researchers to explore the compound's pharmacological potential more comprehensively. The synthetic protocol's high yield and selectivity make it particularly attractive for industrial-scale production, addressing a critical need in drug development pipelines.

Pharmacokinetic studies of 6-chloro-2-ethynylimidazo[1,2-a]pyridine derivatives have revealed both challenges and opportunities. While the compounds generally demonstrate good membrane permeability and metabolic stability, some derivatives exhibit suboptimal bioavailability due to rapid hepatic clearance. Recent efforts in medicinal chemistry have focused on structural modifications to improve these pharmacokinetic properties while maintaining the desired biological activity. A 2024 study in the European Journal of Medicinal Chemistry reported successful optimization of the scaffold through strategic substitutions, resulting in analogs with enhanced oral bioavailability and prolonged half-lives in preclinical models.

Looking forward, the research community anticipates that 6-chloro-2-ethynylimidazo[1,2-a]pyridine will continue to be a valuable scaffold for drug discovery. Its structural features allow for diverse modifications, enabling the exploration of multiple therapeutic targets. Current research efforts are expanding into areas such as anti-infective agents and immunomodulators, with preliminary data showing promise against viral and bacterial pathogens. As more SAR data becomes available and synthetic methodologies continue to improve, this compound class is poised to make significant contributions to the development of novel therapeutics across multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)